0.64Open0.60Pre Close81 Volume237 Open Interest15.00Strike Price5.97KTurnover60.95%IV8.52%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier31DDays to Expiry1.05Extrinsic Value100Contract SizeAmericanOptions Type0.5119Delta0.1520Gamma15.17Leverage Ratio-0.0178Theta0.0056Rho7.77Eff Leverage0.0172Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet